# A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

> **NCT05917509** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 171 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** DTG/3TC
- **DRUG:** Cabotegravir (CAB) LA
- **DRUG:** Rilpivirine (RPV) LA

## Key facts

- **NCT ID:** NCT05917509
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2025-09-16
- **Final completion:** 2026-04-22
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05917509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05917509, "A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05917509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*